
Amber D. Steele
Examiner (ID: 2430, Phone: (571)272-5538 , Office: P/1676 )
| Most Active Art Unit | 1658 |
| Art Unit(s) | 1654, 1639, 1658, 1676 |
| Total Applications | 1302 |
| Issued Applications | 628 |
| Pending Applications | 166 |
| Abandoned Applications | 538 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17988892
[patent_doc_number] => 20220354929
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => PEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/622202
[patent_app_country] => US
[patent_app_date] => 2020-07-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25098
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17622202
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/622202 | PEPTIDES AND USES THEREOF | Jul 7, 2020 | Abandoned |
Array
(
[id] => 17541011
[patent_doc_number] => 11306122
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-04-19
[patent_title] => Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor
[patent_app_type] => utility
[patent_app_number] => 16/897071
[patent_app_country] => US
[patent_app_date] => 2020-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 38
[patent_no_of_words] => 37655
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16897071
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/897071 | Compositions and methods of inhibiting the binding of plasma IgG autoantibodies to serotonin 2A receptor | Jun 8, 2020 | Issued |
Array
(
[id] => 18246822
[patent_doc_number] => 11603395
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-03-14
[patent_title] => Antitumor peptide and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/889020
[patent_app_country] => US
[patent_app_date] => 2020-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8918
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16889020
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/889020 | Antitumor peptide and use thereof | May 31, 2020 | Issued |
Array
(
[id] => 16310929
[patent_doc_number] => 20200289667
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => Targeting Macrophages to Modulate Electrical Conduction in the Heart
[patent_app_type] => utility
[patent_app_number] => 16/889682
[patent_app_country] => US
[patent_app_date] => 2020-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14577
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16889682
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/889682 | Targeting Macrophages to Modulate Electrical Conduction in the Heart | May 31, 2020 | Abandoned |
Array
(
[id] => 16312328
[patent_doc_number] => 20200291066
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => IL-2RBETA BINDING COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/884661
[patent_app_country] => US
[patent_app_date] => 2020-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 111098
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 175
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16884661
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/884661 | IL-2RBETA binding compounds | May 26, 2020 | Issued |
Array
(
[id] => 16312329
[patent_doc_number] => 20200291067
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => IL-2RGAMMA BINDING COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/884726
[patent_app_country] => US
[patent_app_date] => 2020-05-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 110917
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 170
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16884726
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/884726 | IL-2Rgamma binding compounds | May 26, 2020 | Issued |
Array
(
[id] => 17242004
[patent_doc_number] => 20210361747
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => RECOMBINANT THROMBOMODULIN DOMAIN 1 FOR USE IN TREATING EYE DISEASES ASSOCIATED WITH PATHOLOGICAL OCULAR ANGIOGENESIS
[patent_app_type] => utility
[patent_app_number] => 16/882508
[patent_app_country] => US
[patent_app_date] => 2020-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5016
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16882508
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/882508 | Recombinant thrombomodulin domain 1 for use in treating eye diseases associated with pathological ocular angiogenesis | May 23, 2020 | Issued |
Array
(
[id] => 19940485
[patent_doc_number] => 12312607
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-27
[patent_title] => AAV9 affinity agents
[patent_app_type] => utility
[patent_app_number] => 17/613427
[patent_app_country] => US
[patent_app_date] => 2020-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 6174
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613427
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/613427 | AAV9 affinity agents | May 21, 2020 | Issued |
Array
(
[id] => 16598060
[patent_doc_number] => 20210024591
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-28
[patent_title] => TARGETING G3BP AGGREGATION TO PREVENT NEURODEGENERATION
[patent_app_type] => utility
[patent_app_number] => 16/881096
[patent_app_country] => US
[patent_app_date] => 2020-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18186
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16881096
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/881096 | Targeting G3BP aggregation to prevent neurodegeneration | May 21, 2020 | Issued |
Array
(
[id] => 16762361
[patent_doc_number] => 20210107942
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-15
[patent_title] => TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE
[patent_app_type] => utility
[patent_app_number] => 16/878318
[patent_app_country] => US
[patent_app_date] => 2020-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28521
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16878318
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/878318 | TISSUE PROTECTIVE PEPTIDES AND PEPTIDE ANALOGS FOR PREVENTING AND TREATING DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | May 18, 2020 | Abandoned |
Array
(
[id] => 17702899
[patent_doc_number] => 20220202905
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE
[patent_app_type] => utility
[patent_app_number] => 17/610844
[patent_app_country] => US
[patent_app_date] => 2020-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10863
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17610844
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/610844 | COMPOSITION FOR PREVENTING OR TREATING NEUROTROPHIC KERATITIS WHICH CONTAINS PACAP PEPTIDE OR STABILIZED PACAP PEPTIDE | May 13, 2020 | Pending |
Array
(
[id] => 17671010
[patent_doc_number] => 20220184177
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => POLYPEPTIDES FOR TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/607100
[patent_app_country] => US
[patent_app_date] => 2020-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13337
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17607100
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/607100 | Polypeptides for treatment of cancer | May 12, 2020 | Issued |
Array
(
[id] => 17618985
[patent_doc_number] => 11338012
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-24
[patent_title] => BRAF-based polypeptides for treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 15/930660
[patent_app_country] => US
[patent_app_date] => 2020-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 27
[patent_no_of_words] => 13134
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15930660
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/930660 | BRAF-based polypeptides for treatment of cancer | May 12, 2020 | Issued |
Array
(
[id] => 17704554
[patent_doc_number] => 20220204560
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => NOVEL OLIGOPEPTIDE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING THE SAME AS AN ACTIVE INGREDIENT
[patent_app_type] => utility
[patent_app_number] => 17/608263
[patent_app_country] => US
[patent_app_date] => 2020-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5075
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17608263
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/608263 | NOVEL OLIGOPEPTIDE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING THE SAME AS AN ACTIVE INGREDIENT | Apr 28, 2020 | Abandoned |
Array
(
[id] => 18362897
[patent_doc_number] => 20230144488
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => CELL-PENETRATING PEPTIDE AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/918471
[patent_app_country] => US
[patent_app_date] => 2020-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8375
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17918471
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/918471 | Cell-penetrating peptide and use thereof | Apr 27, 2020 | Issued |
Array
(
[id] => 17983840
[patent_doc_number] => 20220349876
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-03
[patent_title] => USE OF DKK1 INHIBITOR IN PREVENTION AND/OR TREATMENT OF TUMOR CACHEXIA AND DISEASES ASSOCIATED WITH DIABETES
[patent_app_type] => utility
[patent_app_number] => 17/624453
[patent_app_country] => US
[patent_app_date] => 2020-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30083
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624453
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/624453 | USE OF DKK1 INHIBITOR IN PREVENTION AND/OR TREATMENT OF TUMOR CACHEXIA AND DISEASES ASSOCIATED WITH DIABETES | Apr 23, 2020 | Pending |
Array
(
[id] => 17704555
[patent_doc_number] => 20220204561
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY
[patent_app_type] => utility
[patent_app_number] => 17/604328
[patent_app_country] => US
[patent_app_date] => 2020-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33213
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17604328
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/604328 | Peptide-based non-proteinaceous cargo delivery | Apr 16, 2020 | Issued |
Array
(
[id] => 16391025
[patent_doc_number] => 20200331966
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => FUSION PROTEIN COMPOSITION(S) COMPRISING MASKED TYPE I INTERFERONS (IFNA AND IFNB) FOR USE IN THE TREATMENT OF CANCER AND METHODS THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/849889
[patent_app_country] => US
[patent_app_date] => 2020-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22240
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16849889
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/849889 | Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof | Apr 14, 2020 | Issued |
Array
(
[id] => 17719094
[patent_doc_number] => 20220211813
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => METHODS FOR TREATMENT OF NIEMANN-PICK DISEASE TYPE C
[patent_app_type] => utility
[patent_app_number] => 17/594167
[patent_app_country] => US
[patent_app_date] => 2020-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16451
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17594167
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/594167 | METHODS FOR TREATMENT OF NIEMANN-PICK DISEASE TYPE C | Apr 12, 2020 | Abandoned |
Array
(
[id] => 17642259
[patent_doc_number] => 20220169997
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => COMPOSITIONS AND METHODS TO MANUFACTURE TUMOR SUPPRESSOR FUSIONS
[patent_app_type] => utility
[patent_app_number] => 17/602733
[patent_app_country] => US
[patent_app_date] => 2020-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68189
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602733
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/602733 | COMPOSITIONS AND METHODS TO MANUFACTURE TUMOR SUPPRESSOR FUSIONS | Apr 10, 2020 | Abandoned |